Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer | Zendy

Eric Hahnen | Zendy; Bianca Lederer | Zendy; Jan Hauke | Zendy; Sibylle Loibl | Zendy; Sandra Kröber | Zendy; Andreas Schneeweiß | Zendy; Carsten Denkert | Zendy; Peter A. Fasching | Zendy; JensUwe Blohmer | Zendy; Christian Jackisch | Zendy; Stefan Paepke | Zendy; Bernd Gerber | Zendy; Sherko Kümmel | Zendy; Christian Schem | Zendy; Guido Neidhardt | Zendy; Jens Huober | Zendy; Kerstin Rhiem | Zendy; Serban Dan Costa | Zendy; Janine Altmüller | Zendy; Claus Hanusch | Zendy; Hölger Thiele | Zendy; Volkmar Müller | Zendy; Peter Nürnberg | Zendy; Thomas Karn | Zendy; Valentiekljudova | Zendy; Michael Untch | Zendy; Gϋnter von Minckwitz | Zendy; Rita K. Schmutzler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

Author(s) -

Eric Hahnen,

Bianca Lederer,

Jan Hauke,

Sibylle Loibl,

Sandra Kröber,

Andreas Schneeweiß,

Carsten Denkert,

Peter A. Fasching,

JensUwe Blohmer,

Christian Jackisch,

Stefan Paepke,

Bernd Gerber,

Sherko Kümmel,

Christian Schem,

Guido Neidhardt,

Jens Huober,

Kerstin Rhiem,

Serban Dan Costa,

Janine Altmüller,

Claus Hanusch,

Hölger Thiele,

Volkmar Müller,

Peter Nürnberg,

Thomas Karn,

Valentiekljudova,

Michael Untch,

Gϋnter von Minckwitz,

Rita K. Schmutzler

Publication year - 2017

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2017.1007

Subject(s) - medicine , carboplatin , breast cancer , oncology , triple negative breast cancer , germline mutation , taxane , regimen , brca mutation , cancer , mutation , chemotherapy , genetics , biology , cisplatin , gene

The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research